<DOC>
	<DOCNO>NCT02931253</DOCNO>
	<brief_summary>The purpose study see study drug metformin help patient overweight atrial fibrillation . This study aim see metformin help patient stay normal sinus rhythm catheter ablation . Metformin investigational use patient atrial fibrillation . Metformin approve Food Drug Administration ( FDA ) use patient type 2 Diabetes Mellitus . Metformin use proper diet exercise program control high blood sugar , show help people lose weight . This study aim look effect metformin weight loss heart rhythm patient atrial fibrillation .</brief_summary>
	<brief_title>Metformin Upstream Therapy Atrial Fibrillation</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>All individual diagnose Atrial Fibrillation choose undergo rhythm control strategy Robert Packer Hospital BMI â‰¥ 27 eligible study . All subject must able understand willing sign write informed consent document . Individuals already take metformin antidiabetic medication include insulin , diagnosis diabetes , know allergy FDAlabeled contraindication take metformin , eGFR 30 mL/min per 1.73 m2 clinical diagnosis advance renal disease , , acute chronic metabolic acidosis ( serum bicarbonate &lt; 22 mEq/L ) , history significant alcohol use ( &gt; 2 drinks/day average ) , history hepatic dysfunction ( serum bilirubin 1.5X great upper limit normal ) , history New York Heart Association ( NYHA ) Class III IV heart failure , pregnant exclude trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>